Balazs Halmos, MD | Authors


Clinical Trials Excite Treatment Landscape for Early-Stage EGFR-Mutated NSCLC

September 18, 2020

Balazs Halmos, MD, MS, discusses 2 major presentations from the 2020 American Society of Clinical Oncology Virtual Scientific Program that appeared promising for the treatment of patients with EGFR-mutant non–small cell lung cancer.

Immune Checkpoint Inhibitors in NSCLC

May 07, 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the variety of immune checkpoint inhibitors that are currently being explored as treatments for patients with non-small cell lung cancer (NSCLC).